Avanir Sues Par, Actavis To Block Generic Nuedexta

Law360, New York (August 11, 2011, 12:44 PM EDT) -- Avanir Pharmaceuticals Inc. sued Actavis Inc. and Par Pharmaceutical Inc. in Delaware on Wednesday alleging their planned generic versions of involuntary-emotion drug Nuedexta would violate two patents.

Avanir launched its suits in response to abbreviated new drug applications filed by Actavis and Par with the U.S. Food and Drug Administration in the hopes of manufacturing and marketing their own versions of Nuedexta, which is used to treat involuntary laughing or crying episodes in patients with certain underlying neurologic conditions.

The company claims the ANDAs violate the...
To view the full article, register now.